Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin + doxorubicin + cyclophosphamide
- Development stage
- Phase 3
- Lead developer
- University of Wisconsin–Madison
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This neoadjuvant chemotherapy regimen is being evaluated by the University of Wisconsin, Madison, for the treatment of triple-negative breast cancer (TNBC). The regimen consists of a sequential approach: patients first receive low-dose weekly carboplatin and paclitaxel, followed by dose-dense doxorubicin (Adriamycin) and cyclophosphamide (AC). Paclitaxel is a taxane that stabilizes microtubules to inhibit cell division, while carboplatin is a platinum-based agent that causes DNA cross-linking. Doxorubicin acts as an anthracycline that intercalates DNA and inhibits topoisomerase II, and cyclophosphamide is an alkylating agent. This combination is designed to maximize pathologic complete response (pCR) rates in patients with hormone receptor-negative and HER2-negative breast cancer before surgical intervention.
- Other names
- Neoadjuvant Carboplatin/Paclitaxel followed by dose-dense ACCarboplatin + Paclitaxel followed by Doxorubicin + CyclophosphamideNeoadjuvant Carboplatin/Paclitaxel/AC
02
Targets
TOP2A (DNA topoisomerase II)N7-G/A (DNA purine N7 positions)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + carboplatin + doxorubicin + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin + doxorubicin + cyclophosphamide.